BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 21693322)

  • 21. Host CD25+CD4+Foxp3+ regulatory T cells primed by anti-CD137 mAbs inhibit graft-versus-host disease.
    Kim J; Kim W; Kim HJ; Park S; Kim HA; Jung D; Choi HJ; Park SJ; Mittler RS; Cho HR; Kwon B
    Biol Blood Marrow Transplant; 2012 Jan; 18(1):44-54. PubMed ID: 21958951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
    Prigozhina TB; Elkin G; Khitrin S; Slavin S
    Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD).
    Cao T; Soto A; Zhou W; Wang W; Eck S; Walker M; Harriman G; Li L
    Cell Immunol; 2009; 258(1):65-71. PubMed ID: 19410243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adoptive transfer of small numbers of DX5+ cells alleviates graft-versus-host disease in a murine model of semiallogeneic bone marrow transplantation: a potential role for NKT lymphocytes.
    Margalit M; Ilan Y; Ohana M; Safadi R; Alper R; Sherman Y; Doviner V; Rabbani E; Engelhardt D; Nagler A
    Bone Marrow Transplant; 2005 Jan; 35(2):191-7. PubMed ID: 15558045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Experimental study of the inhibiting effect of the lentiviral vector mediated herpes simplex virus-thymidine kinase/ganciclovir on GVHD].
    Xu KL; Zhu F; Du B; Gao F; Cheng H; Pan XY
    Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):303-7. PubMed ID: 17877157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
    Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease.
    Welniak LA; Wang Z; Sun K; Kuziel W; Anver MR; Blazar BR; Murphy WJ
    Exp Hematol; 2004 Mar; 32(3):318-24. PubMed ID: 15003318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Role of TJU103 in prevention of graft-versus-host disease after allogeneic stem cell transplantation in mice].
    Wang SB; Guo KY; Hu DM; Yin B
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):810-3. PubMed ID: 16793606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complete allogeneic hematopoietic chimerism achieved by in utero hematopoietic cell transplantation and cotransplantation of LLME-treated, MHC-sensitized donor lymphocytes.
    Hayashi S; Hsieh M; Peranteau WH; Ashizuka S; Flake AW
    Exp Hematol; 2004 Mar; 32(3):290-9. PubMed ID: 15003315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.
    Koenecke C; Lee CW; Thamm K; Föhse L; Schafferus M; Mittrücker HW; Floess S; Huehn J; Ganser A; Förster R; Prinz I
    J Immunol; 2012 Sep; 189(6):2890-6. PubMed ID: 22869903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infusion of Lin- bone marrow cells results in multilineage macrochimerism and skin allograft tolerance in minimally conditioned recipient mice.
    Anam K; Amare MF; Zins SR; Davis TA
    Transpl Immunol; 2010 Oct; 24(1):69-75. PubMed ID: 20950686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation.
    Blazar BR; Taylor PA; Fitzsimmons WE; Vallera DA
    J Immunol; 1994 Aug; 153(4):1836-46. PubMed ID: 7519216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppressive activity in recipients of non-T cell-depleted allogeneic bone marrow transplants: role of T cell-depleted syngeneic marrow.
    Sykes M
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():30-3. PubMed ID: 2534057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [ALA-PDT alleviates graft-versus-host disease in mice following allogenic bone marrow transplantation].
    Ran HH; Pan KL; Zhang R; Wang YF
    Zhongguo Dang Dai Er Ke Za Zhi; 2006 Oct; 8(5):408-12. PubMed ID: 17052403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effects of immature dendritic cells to express CCR7 on graft-versus-host disease in allogeneic bone marrow transplant mouse model].
    Li DP; Wu JQ; Huang YH; Song LX; Gu HH; Gao CL; Li ZY; Pan XY; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2013 Sep; 34(9):782-7. PubMed ID: 24103877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
    Blazar BR; Taylor PA; Vallera DA
    J Immunol; 1994 Apr; 152(7):3665-74. PubMed ID: 8144942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of BCL1 leukemia by transplantation of low density fractions of allogeneic bone marrow and spleen cells.
    Palathumpat V; Holm B; Dejbakhsh-Jones S; Strober S
    J Immunol; 1992 May; 148(10):3319-26. PubMed ID: 1578152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.